Jonathan Trent on Trabectedin for Soft Tissue Sarcoma

December 22, 2015
Jonathan Trent, MD, PhD

Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin to treat patients with soft tissue sarcoma. 

Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin (Yondelis) to treat patients with soft tissue sarcoma. 

The FDA approved trabectedin in October 2015 for patients with liposarcoma and leiomyosarcoma who were previously treated with chemotherapy that included an anthracycline. 

The approval was based on a large, randomized study that found trabectedin was superior to dacarbazine chemotherapy in terms of response rates, duration of response, overall survival, and progression-free survival.